President Donald Trump on April 18 signed an executive order, directing federal agencies to accelerate U.S. research into ibogaine, a psychedelic compound used in some countries for conditions like post-traumatic stress disorder. The action includes a $50 million federal investment and a pathway for "desperately ill patients" to access the substance under the Food and Drug Administration's Right To Try rule. This initiative aims to explore ibogaine's potential, particularly for veterans, as Mr. Trump stated.

The executive order, signed at a White House event, specifically mandates that the Food and Drug Administration (FDA) begin processes to allow human trials for ibogaine. Dr. Marty Makary, the FDA commissioner, stated that three psychedelics, including ibogaine, will join the National Priority Voucher pilot program.

This program is designed to reduce review times for certain drugs. Commissioner Makary emphasized the "unmet public health need" and the existence of "potentially promising treatments." He noted the urgency surrounding these investigations. This federal commitment follows a similar move in Texas, where Governor Greg Abbott signed legislation last year approving $50 million for ibogaine research.

The convergence of state and federal interest marks a significant shift for a substance long classified as Schedule I by the Drug Enforcement Administration (DEA). This classification places ibogaine alongside substances like heroin, indicating a high potential for abuse and no accepted medical use. Such a designation has historically made research extremely difficult.

Researchers have long sought to change this status. Ibogaine is a naturally occurring compound derived from the root bark of *Tabernanthe iboga*, a shrub indigenous to West Central Africa. Traditional healers have used it for centuries in spiritual ceremonies and to treat various ailments.

In modern contexts, it has gained a reputation in some unregulated clinics, often outside the U.S., for treating addiction, depression, anxiety, and trauma. Patients often seek these treatments abroad. "The federal government will make a $50 million research investment into ibogaine," Mr. Trump announced during the signing event.

He added that the government was also opening a pathway for ibogaine to be administered to "desperately ill patients" under the FDA's Right To Try rule. This rule allows patients with life-threatening conditions to access experimental treatments not yet fully approved by the FDA, provided certain criteria are met. It is a controversial pathway.

Health and Human Services Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan attended the White House event. Trump stated that the order would "dramatically accelerate access to new medical research and treatments based on psychedelic drugs." He described their potential as "life-changing." The President highlighted veteran suicide rates, adding, "Everybody is so strongly in favor of this.

It's for a lot of people, but it's for our veterans in particular." He expressed hope that these treatments could have a "tremendous impact" domestically and internationally. Here is what the study actually says: While the enthusiasm for ibogaine is palpable, particularly among proponents of psychedelic-assisted therapy, the scientific evidence supporting its widespread use remains limited. Most of the current data comes from small observational studies and open-label trials.

These studies lack the rigor of double-blind, placebo-controlled randomized clinical trials (RCTs), which are considered the gold standard for establishing drug safety and efficacy. Only one such RCT on ibogaine has been completed to date. This is a critical distinction for assessing confidence levels.

Before you panic, read the methodology. Observational studies, while useful for generating hypotheses, cannot definitively prove cause and effect. They simply observe what happens without controlling for other variables.

Open-label trials, where both researchers and participants know who is receiving the active drug, introduce potential biases. Participants might experience a placebo effect, or researchers might interpret outcomes more favorably. Rigorous, blinded studies are essential to isolate a drug's true effect from other influences.

This is how we build a strong evidence base in medicine. The headline is dramatic. The data is not yet robust enough to warrant widespread clinical adoption.

Researchers generally agree that more large-scale, well-controlled clinical trials are necessary before ibogaine can be deemed safe or effective for any condition. The compound's mechanism of action, while complex, involves interacting with multiple neurotransmitter systems, including opioid, serotonin, and dopamine receptors. This broad activity contributes to its psychedelic effects and its potential, but also to its complex side effect profile.

Understanding these interactions is key to safe application. One significant concern surrounding ibogaine is its potential for dangerous heart rhythm disturbances. A 2023 review of 24 studies, encompassing 705 individuals, described the risk of death from cardiac problems as "worrying." The review specifically noted at least 27 deaths reported after individuals took ibogaine.

These risks are not trivial. Patients considering ibogaine, even in a research setting, must undergo thorough cardiac screening. Unregulated clinics, often found in locations like Mexico or the Caribbean, may not provide this essential medical oversight, increasing patient danger.

This lack of medical supervision is a serious public health issue. Commissioner Makary's comments underscore the FDA's cautious yet urgent approach. "This is an unmet public health need and there are potentially promising treatments," Makary stated. The National Priority Voucher pilot program, which will now include ibogaine, aims to incentivize the development of new drugs for certain neglected diseases or conditions that align with U.S. national health priorities.

By offering a voucher that can be sold to another company to expedite the review of a different drug, the program creates a financial incentive for research into challenging areas. This mechanism could significantly speed up the research timeline for ibogaine and other psychedelics. CBS News first reported the President's intention to sign the order earlier this week, indicating that discussions about this move had been underway for some time.

The federal government's specific strategies for facilitating further research beyond the initial $50 million investment were still being finalized in internal discussions, CBS News reported. This suggests a complex rollout ahead. Why It Matters: This executive order represents a significant policy shift, moving ibogaine from the fringes of illicit substances into the realm of legitimate medical inquiry.

For veterans struggling with PTSD and individuals battling opioid dependence, this could eventually open doors to new treatment options where current therapies fall short. The opioid crisis continues to claim thousands of lives annually. New approaches are desperately needed.

However, the move also highlights the delicate balance between accelerating access to potentially beneficial treatments and ensuring patient safety through rigorous scientific validation. It means greater scrutiny of both the science and the delivery of care. Key Takeaways: - President Trump's executive order directs federal agencies to accelerate research into ibogaine, a Schedule I psychedelic compound. - The order includes a $50 million federal research investment and allows for Right To Try access for "desperately ill patients." - Scientific evidence for ibogaine's efficacy is currently limited, primarily consisting of small observational studies, with only one completed double-blind, placebo-controlled trial. - Ibogaine carries known cardiac risks, with at least 27 reported deaths linked to its use, necessitating careful medical oversight in any future trials.

Looking ahead, the FDA's initiation of processes for human trials will be the immediate next step. Researchers will need to submit detailed protocols outlining study design, patient selection, dosing, and safety monitoring. The allocation of the $50 million federal funding will also determine which research institutions and projects receive support.

Stakeholders will closely watch how the FDA balances the call for accelerated access with its mandate for patient safety, particularly given ibogaine's known cardiac risks. The trajectory of these initial human trials will shape future policy decisions and determine ibogaine's path toward potential medical integration.

Key Takeaways
— - President Trump's executive order directs federal agencies to accelerate research into ibogaine, a Schedule I psychedelic compound.
— - The order includes a $50 million federal research investment and allows for Right To Try access for "desperately ill patients."
— - Scientific evidence for ibogaine's efficacy is currently limited, primarily consisting of small observational studies, with only one completed double-blind, placebo-controlled trial.
— - Ibogaine carries known cardiac risks, with at least 27 reported deaths linked to its use, necessitating careful medical oversight in any future trials.

Source: CBS News

Reporting by Dmitri Sokolov, Horizon Reports — April 18, 2026